Literature DB >> 10208381

Blockade of nicotine self-administration with nicotinic antagonists in rats.

S S Watkins1, M P Epping-Jordan, G F Koob, A Markou.   

Abstract

The reinforcing properties of a variety of drugs abused by humans have been investigated using the technique of intravenous self-administration in the rat. To examine the effect of nicotine dose on nicotine self-administration, Wistar rats were allowed to self-administer various doses of nicotine using a within-subjects Latin square design. An inverted U-shaped dose response curve was obtained, with the highest rates of responding at the 0.03 mg/kg/inf dose. With 1-h daily nicotine self-administration sessions, rats did not appear dependent on nicotine 24 h later, as indicated by the absence of somatic signs of withdrawal after subcutaneous injection of a nicotinic acetylcholine receptor antagonist, mecamylamine (0.57 mg/kg). In another set of studies, pretreatment with subcutaneous mecamylamine or dihydro-beta-erythroidine, two nicotinic acetylcholine receptor antagonists, resulted in significant dose-dependent reductions in nicotine self-administration, at two nicotine doses (0.03 and 0.06 mg/kg/inf). These results indicate that nicotine is an effective reinforcer in Wistar rats under the present parameters, and that these reinforcing effects are mediated by activation of nicotinic acetylcholine receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208381     DOI: 10.1016/s0091-3057(98)00226-3

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  101 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats.

Authors:  Neil E Paterson; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

3.  AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Authors:  Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

4.  Nicotine e-cigarette vapor inhalation effects on nicotine & cotinine plasma levels and somatic withdrawal signs in adult male Wistar rats.

Authors:  Christian Montanari; Leslie K Kelley; Tony M Kerr; Maury Cole; Nicholas W Gilpin
Journal:  Psychopharmacology (Berl)       Date:  2019-11-23       Impact factor: 4.530

5.  Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

Authors:  Janice W Smith; Adrian Mogg; Elisiana Tafi; Eleanor Peacey; Ian A Pullar; Philip Szekeres; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2006-11-18       Impact factor: 4.530

6.  Structure-activity relationship studies of sulfonylpiperazine analogues as novel negative allosteric modulators of human neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Daniel J Carper; Tatiana F González-Cestari; Bitna Yi; Kiran Mahasenan; Ryan E Pavlovicz; Martin L Dalefield; Robert S Coleman; Chenglong Li; Dennis B McKay
Journal:  J Med Chem       Date:  2011-11-18       Impact factor: 7.446

7.  Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.

Authors:  Matthias E Liechti; Athina Markou
Journal:  Eur J Pharmacol       Date:  2006-10-17       Impact factor: 4.432

Review 8.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 9.  Smoking cessation: significance and implications for children.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

10.  Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.

Authors:  Mark G LeSage; David Shelley; Jason T Ross; F Ivy Carroll; William A Corrigall
Journal:  Pharmacol Biochem Behav       Date:  2008-09-09       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.